膜杰作
Star Staining
抗体来源（Source）
Monoclonal Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号（Clone）
101F
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG2a | Mouse Kappa
偶联（Conjugate）
Unconjugated
抗体类型（Antibody Type）
Recombinant Monoclonal
种属反应性（Reactivity）
Virus
特异性（Specificity）
This product is a specific antibody specifically reacts with RSV-F0.
应用（Application）
| Application | Recommended Usage |
| ELISA | 0.2-78 ng/mL |
纯度（Purity）
>95% as determined by SDS-PAGE.
纯化（Purification）
Protein A purified/ Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Monoclonal Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
活性（Bioactivity）-ELISA
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) (Cat. No. AM309a) with a linear range of 0.2-10 ng/mL (QC tested).
Protocol
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) (Cat. No. AM309a) with a linear range of 0.2-10 ng/mL (QC tested).
Protocol
背景（Background）
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Antibody 101F, target epitopes that have been mapped to linear regions in the F1 subunit, referred to as antigenic site IV.
